JAPAN TISSUE ENGINEERING CO., LTD. Financials Japan Tissue Engineering Co., Ltd.
Equities
7774
JP3389610001
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 660 JPY | +1.69% |
|
+2.33% | +30.43% |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 40,529 | 23,391 | 30,661 | 20,833 | 21,158 | 26,803 | - |
| Enterprise Value (EV) 1 | 34,606 | 17,643 | 25,386 | 15,900 | 17,024 | 26,803 | 26,803 |
| P/E ratio | -122 x | -81.5 x | -65.7 x | -41.8 x | -29 x | 287 x | 28 x |
| Yield | - | - | - | - | - | 1.52% | - |
| Capitalization / Revenue | 17.2 x | 10.1 x | 13.6 x | 9.91 x | 10.4 x | 9.46 x | 6.1 x |
| EV / Revenue | 17.2 x | 10.1 x | 13.6 x | 9.91 x | 10.4 x | 9.46 x | 6.1 x |
| EV / EBITDA | -176,160,081 x | -210,667,532 x | -90,543,888 x | - | - | - | - |
| EV / FCF | -82,042,457 x | -138,411,062 x | -65,654,595 x | -60,963,950 x | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - |
| Price to Book | 5.12 x | 3.07 x | 4.28 x | 3.13 x | 3.56 x | 4.86 x | 4.42 x |
| Nbr of stocks (in thousands) | 40,610 | 40,610 | 40,610 | 40,610 | 40,610 | 40,610 | - |
| Reference price 2 | 998.0 | 576.0 | 755.0 | 513.0 | 521.0 | 660.0 | 660.0 |
| Announcement Date | 25/04/19 | 27/04/20 | 28/04/21 | 26/04/22 | 27/04/23 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,357 | 2,309 | 2,257 | 2,103 | 2,032 | 2,832 | 4,393 |
| EBITDA | -230.1 | -111 | -338.6 | - | - | - | - |
| EBIT 1 | -349 | -235 | -466 | -498 | -728.1 | 95 | 959 |
| Operating Margin | -14.81% | -10.18% | -20.65% | -23.68% | -35.82% | 3.35% | 21.83% |
| Earnings before Tax (EBT) | -339 | -229 | -462 | -494 | -725.5 | - | 959 |
| Net income 1 | -333 | -287 | -466 | -497 | -729.3 | 95 | 959 |
| Net margin | -14.13% | -12.43% | -20.65% | -23.63% | -35.88% | 3.35% | 21.83% |
| EPS 2 | -8.210 | -7.070 | -11.49 | -12.26 | -17.96 | 2.300 | 23.60 |
| Free Cash Flow | -494 | -169 | -467 | -341.7 | - | - | - |
| FCF margin | -20.96% | -7.32% | -20.69% | -16.25% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | 10.00 | - |
| Announcement Date | 25/04/19 | 27/04/20 | 28/04/21 | 26/04/22 | 27/04/23 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 983 | 916 | 980 | 615 | 422 | 550 | 972 | 471 | 589 | 662.1 | 584.5 | 1,246 | 539 | 675 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -271 | -272 | -267 | -72 | -267.1 | -153 | -420 | -204 | -104 | 14.21 | -25.06 | -10 | -40.82 | -32 |
| Operating Margin | -27.57% | -29.69% | -27.24% | -11.71% | -63.29% | -27.82% | -43.21% | -43.31% | -17.66% | 2.15% | -4.29% | -0.8% | -7.57% | -4.74% |
| Earnings before Tax (EBT) | -269 | -270 | -265 | -72 | -267 | - | -419 | -203 | - | 14 | - | -9 | -41 | - |
| Net income | -271 | -272 | -267 | -73 | -268 | - | -421 | -204 | - | 13.84 | - | -11 | -42 | - |
| Net margin | -27.57% | -29.69% | -27.24% | -11.87% | -63.51% | - | -43.31% | -43.31% | - | 2.09% | - | -0.88% | -7.79% | - |
| EPS | -6.680 | -6.700 | -6.590 | -1.800 | -6.600 | - | -10.38 | -5.030 | - | 0.3400 | - | -0.2900 | -1.030 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/10/19 | 30/10/20 | 29/10/21 | 31/01/22 | 27/07/22 | 31/10/22 | 31/10/22 | 27/01/23 | 27/04/23 | 31/07/23 | 31/10/23 | 31/10/23 | 30/01/24 | - |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 5,923 | 5,748 | 5,275 | 4,933 | 4,134 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -494 | -169 | -467 | -342 | - | - | - |
| ROE (net income / shareholders' equity) | -4.1% | -3.7% | -6.3% | -7.2% | -11.6% | 1.7% | 16.6% |
| ROA (Net income/ Total Assets) | -3.81% | -2.66% | -5.58% | -6.29% | -10% | 1.4% | - |
| Assets 1 | 8,730 | 10,779 | 8,357 | 7,906 | 7,284 | 6,786 | - |
| Book Value Per Share 2 | 195.0 | 188.0 | 176.0 | 164.0 | 146.0 | 136.0 | 149.0 |
| Cash Flow per Share | -5.270 | -4.010 | -8.320 | -9.180 | -14.70 | - | - |
| Capex | 98 | 85 | 68 | 103 | 142 | - | - |
| Capex / Sales | 4.16% | 3.68% | 3.01% | 4.88% | 6.99% | - | - |
| Announcement Date | 25/04/19 | 27/04/20 | 28/04/21 | 26/04/22 | 27/04/23 | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.43% | 170M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- 7774 Stock
- Financials Japan Tissue Engineering Co., Ltd.
